Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations

Among attempts to delay development of resistance to tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor (EGFR), intercalated therapy has not been properly evaluated. In a phase II trial, 38 pati...

Full description

Bibliographic Details
Main Authors: Zwitter, Matjaz, Rajer, Mirjana, Stanic, Karmen, Vrankar, Martina, Doma, Andrej, Cuderman, Anka, Grmek, Marko, Kern, Izidor, Kovac, Viljem
Format: Online
Language:English
Published: Taylor & Francis 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074447/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074447/

Similar Items